Oculis (NASDAQ:OCS) Trading Up 4.8% – What’s Next?

Oculis Holding AG (NASDAQ:OCS)’s share price traded up 4.8% during trading on Monday . The stock traded as high as $15.10 and last traded at $14.71. 13,145 shares changed hands during trading, a decline of 60% from the average session volume of 33,229 shares. The stock had previously closed at $14.03.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Oculis in a report on Wednesday. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $29.20.

Oculis Stock Down 4.6 %

The company has a current ratio of 5.27, a quick ratio of 5.27 and a debt-to-equity ratio of 0.01. The stock’s 50-day moving average price is $12.73 and its 200-day moving average price is $12.15. The company has a market cap of $640.37 million, a P/E ratio of -8.88 and a beta of 0.30.

Oculis (NASDAQ:OCS) last announced its quarterly earnings results on Tuesday, August 27th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.13). The firm had revenue of $0.27 million during the quarter, compared to the consensus estimate of $0.28 million. Oculis had a negative return on equity of 61.33% and a negative net margin of 7,679.05%. As a group, research analysts forecast that Oculis Holding AG will post -2.19 EPS for the current year.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.